Oncolytics Biotech Reports Updated Anal Cancer Data

Oncolytics Biotech Inc. announced updated results from the GOBLET study evaluating pelareorep in combination with atezolizumab for patients with second-line or later metastatic squamous cell anal carcinoma (SCAC). The combination achieved an objective response rate (ORR) of 30%, more than double the historical benchmark of 13.8% for the only FDA-approved immunotherapy for 2L SCAC. The median duration of response was 15.5 months compared to 9.5 months for the current standard of care. The company plans to discuss a potential single-arm study for accelerated approval with the FDA in Q1 2026.